In a regulatory filing, Krystal Biotech disclosed that its CEO Krish Krishnan sold 50K shares of common stock on September 11th in a total transaction size of $6.36M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KRYS:
- Krystal Biotech to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
- Krystal Biotech initiated with a Buy at Berenberg
- Krystal Biotech’s KB408 granted Orpah Drug Designation in AATD
- Krystal Biotech Announces Orphan Drug Designation Granted to KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
- Krystal Biotech granted orphan status for antitrypsin deficiency treatment